Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV)

CITATION: Bekker, A. et al. 2020. Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 72 (11): 2032–2034. doi:10.1093/cid/ciaa1026The original publication is available at https://academic.oup.com/cid/Abacavir is a potential option for prophylaxis and early treatment of human immunodeficiency virus (HIV), but no data are available in neonates. Ten neonates administered a single abacavir dose of 8 mg/kg before 15 days of life had substantially higher exposures than those reported in infants and children, with no reported adverse events.https://academic.oup.com/cid/article/72/11/2032/5874909?login=truePublishers versio